Pfizer has granted exclusive development and marketing rights to ChemRar group company SatRx for their DPP(1)-IVi compound, PF-00734200 for type 2 diabetes (T2D).

T2D is one of the most burdensome chronic non-communicable diseases, which is fast reaching epidemic proportions throughout the world.

Under the terms of the license, SatRx has received exclusive worldwide rights (excluding China) for the development and commercialization of PF-00734200 as monotherapy or in combination with certain other.

The ChemRar group company will pay royalties and milestone payments based on commercialization activities.

ChemRar HTC board member Nikolay Savchuk said SatRx is going to register the new drug to the Russian market and will further establish breakthrough therapies for treating diabetes synergistically combining DPP-IVi with TGR5 agonists and other novel small molecule drug candidates in its R&D portfolio.

"We aspire to further expand our collaboration with Pfizer in the framework of the MOU we signed in 2011," Savchuk said.

SatRx general manager Yulia Baybikova said this licensing agreement with Pfizer provides SatRx with essential background for development of fully innovative tools to tune the metabolism of patients with T2D and obesity.

"Synergistic actions of DPP-IVi and proprietary new SatRx molecules active in the incretin metabolic cascade will provide significant therapeutic benefits and promises to increase patient compliance and quality of life," Baybikova said.